Pediatrix Medical Group, Inc. $MD Shares Acquired by Boston Partners

Key Points

• Boston Partners increased its stake in Pediatrix Medical Group by 1.3%, holding approximately 1,981,889 shares valued at $27.99 million as of the latest SEC filing.
• Analysts have adjusted their price targets for Pediatrix Medical Group, with Macquarie raising its target from $19.00 to $20.00 and UBS Group lifting it to $16.50, indicating a generally positive outlook.
• Pediatrix Medical Group reported a quarterly earnings per share (EPS) of $0.53, exceeding expectations, despite a 7.1% decline in revenue year-over-year.

Boston Partners grew its position in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,981,889 shares of the company's stock after acquiring an additional 25,536 shares during the period. Boston Partners owned about 2.31% of Pediatrix Medical Group worth $27,990,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. XTX Topco Ltd purchased a new stake in shares of Pediatrix Medical Group in the fourth quarter valued at about $169,000. Principal Financial Group Inc. lifted its stake in shares of Pediatrix Medical Group by 6.2% in the first quarter. Principal Financial Group Inc. now owns 586,190 shares of the company's stock valued at $8,494,000 after purchasing an additional 34,266 shares during the period. GAMMA Investing LLC lifted its stake in shares of Pediatrix Medical Group by 219.5% in the first quarter. GAMMA Investing LLC now owns 2,569 shares of the company's stock valued at $37,000 after purchasing an additional 1,765 shares during the period. SG Americas Securities LLC lifted its stake in shares of Pediatrix Medical Group by 194.0% in the first quarter. SG Americas Securities LLC now owns 38,405 shares of the company's stock valued at $556,000 after purchasing an additional 25,343 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of Pediatrix Medical Group by 53.1% in the fourth quarter. Deutsche Bank AG now owns 74,023 shares of the company's stock valued at $971,000 after purchasing an additional 25,663 shares during the period. Hedge funds and other institutional investors own 97.71% of the company's stock.

Analysts Set New Price Targets

MD has been the subject of several recent analyst reports. Zacks Research upgraded shares of Pediatrix Medical Group to a "strong-buy" rating in a research note on Monday, August 11th. UBS Group raised their price objective on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the company a "neutral" rating in a research note on Thursday, August 14th. Finally, Macquarie raised their price objective on shares of Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.75.

Pediatrix Medical Group Price Performance

MD traded down $0.2140 during midday trading on Wednesday, reaching $16.2760. 704,196 shares of the company's stock were exchanged, compared to its average volume of 867,985. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. The stock has a market capitalization of $1.42 billion, a PE ratio of 12.62 and a beta of 1.21. The business's 50-day moving average price is $13.67 and its 200 day moving average price is $13.90. Pediatrix Medical Group, Inc. has a 1-year low of $10.06 and a 1-year high of $17.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $0.11. The business had revenue of $468.84 million during the quarter, compared to analyst estimates of $464.37 million. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The company's revenue was down 7.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 earnings per share. As a group, equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.